ROC-derived cutoffs of 31 months of initiation of TMZ therapy, low-to-intermediate MGMT positivity (40% tumor cells), and MGMT h-score of 80 all had a sensitivity of at least 80% and a specificity of at least 70% to predict response. Here, MGMT is linked to neoplasm.